Joseph F Bower

Summary

Affiliation: Sanofi Pasteur

Publications

  1. ncbi HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies
    Joseph F Bower
    University of Pittsburgh, School of Medicine, Department of Medicine, Division of Infectious Diseases, Scaife Hall, Room S871, 3550 Terrace Street, Pittsburgh, PA 15261, USA
    Vaccine 24:5442-51. 2006
  2. ncbi Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d
    Joseph F Bower
    Department of Medicine, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, USA
    J Virol 78:4710-9. 2004
  3. ncbi DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1
    Joseph F Bower
    Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, School of Medicine, Pittsburgh, PA 15261, USA
    Virology 328:292-300. 2004
  4. ncbi Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies
    Kelly R Young
    Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania 15261, USA
    AIDS Res Hum Retroviruses 20:1259-68. 2004
  5. ncbi C3d enhances immune responses using low doses of DNA expressing the HIV-1 envelope from codon-optimized gene sequences
    Joseph F Bower
    Department of Medicine, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Curr HIV Res 3:191-8. 2005
  6. ncbi A minimum CR2 binding domain of C3d enhances immunity following vaccination
    Joseph F Bower
    Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, School of Medicine, Pittsburgh, PA, 15261, USA
    Adv Exp Med Biol 586:249-64. 2006
  7. ncbi Cutting edge: C3d functions as a molecular adjuvant in the absence of CD21/35 expression
    Karen M Haas
    Department of Immunology, Duke University Medical Center, Durham, NC 27710, USA
    J Immunol 172:5833-7. 2004

Collaborators

  • Xinzhen Yang
  • Ted M Ross
  • Karen M Haas
  • Kelly R Young
  • Julie A Oliver
  • Thomas F Tedder
  • Benjamin E Teal
  • Jonathan C Poe
  • David R Karp
  • Yvonne Brooks
  • Thomas D Green
  • John H Weis
  • Franklin R Toapanta

Detail Information

Publications7

  1. ncbi HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies
    Joseph F Bower
    University of Pittsburgh, School of Medicine, Department of Medicine, Division of Infectious Diseases, Scaife Hall, Room S871, 3550 Terrace Street, Pittsburgh, PA 15261, USA
    Vaccine 24:5442-51. 2006
    ....
  2. ncbi Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d
    Joseph F Bower
    Department of Medicine, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, USA
    J Virol 78:4710-9. 2004
    ..Therefore, DNA vaccines expressing trimeric envelopes coupled to mC3d, expressed in vivo from codon-optimized sequences, elicit low titers of neutralizing antibodies against primary isolates of HIV-1...
  3. ncbi DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1
    Joseph F Bower
    Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, School of Medicine, Pittsburgh, PA 15261, USA
    Virology 328:292-300. 2004
    ..The fusion of sCD4 to the HIV-1 envelope exposes neutralizing epitopes that elicit broad protective immunity when the fusion complex is coupled with the molecular adjuvant, C3d...
  4. ncbi Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies
    Kelly R Young
    Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania 15261, USA
    AIDS Res Hum Retroviruses 20:1259-68. 2004
    ..However, the introduction of this same sequence into an R5X4-tropic envelope was ineffective in eliciting improved cross-clade neutralizing antibodies...
  5. ncbi C3d enhances immune responses using low doses of DNA expressing the HIV-1 envelope from codon-optimized gene sequences
    Joseph F Bower
    Department of Medicine, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Curr HIV Res 3:191-8. 2005
    ..Therefore, both codon-optimization of env sequences and C3d conjugation to Env appear to enhance anti-Env antibodies in an independent and additive manner...
  6. ncbi A minimum CR2 binding domain of C3d enhances immunity following vaccination
    Joseph F Bower
    Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, School of Medicine, Pittsburgh, PA, 15261, USA
    Adv Exp Med Biol 586:249-64. 2006
    ..This CR2-binding domain specific 28 amino acid peptide can substitute for the entire C3d molecule and enhance immunity. These results indicate that the adjuvant properties of C3d are associated with CR2 interaction...
  7. ncbi Cutting edge: C3d functions as a molecular adjuvant in the absence of CD21/35 expression
    Karen M Haas
    Department of Immunology, Duke University Medical Center, Durham, NC 27710, USA
    J Immunol 172:5833-7. 2004
    ..Thus, C3d can function as a molecular adjuvant in the absence of CD21/35 expression...